Filana Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Filana Therapeutics, Inc. (FLNA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$90.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-03-12
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$12.54M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$10.81M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$44.22M, a 818.51% decline year-over-year.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$23.40M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$90.97M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$68.14M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$97.22M.
- Filana Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$76.25M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$12.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$23.35M derived: sum of 2 quarters · filed 2026-03-12 | -$67.57M derived: sum of 3 quarters · filed 2026-03-12 | -$90.97M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$10.81M 10-Q · filed 2025-11-12 | -$55.03M derived: sum of 2 quarters · filed 2025-11-12 | -$78.43M 10-Q · filed 2025-11-12 | -$106.03M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | -$44.22M 10-Q · filed 2025-08-14 | -$67.63M 10-Q · filed 2025-08-14 | -$95.22M derived: sum of 3 quarters · filed 2026-03-12 | -$123.17M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | -$23.40M 10-Q · filed 2025-05-08 | -$51.00M derived: sum of 2 quarters · filed 2026-03-12 | -$78.94M derived: sum of 3 quarters · filed 2026-03-12 | -$72.79M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | -$27.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$55.54M derived: sum of 2 quarters · filed 2026-03-12 | -$49.38M derived: sum of 3 quarters · filed 2026-03-12 | -$68.14M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$27.94M 10-Q · filed 2025-11-12 | -$21.79M derived: sum of 2 quarters · filed 2025-11-12 | -$40.54M 10-Q · filed 2025-11-12 | -$61.46M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $6.16M 10-Q · filed 2025-08-14 | -$12.60M 10-Q · filed 2025-08-14 | -$33.51M derived: sum of 3 quarters · filed 2026-03-12 | -$59.16M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$18.75M 10-Q · filed 2025-05-08 | -$39.67M derived: sum of 2 quarters · filed 2026-03-12 | -$65.32M derived: sum of 3 quarters · filed 2026-03-12 | -$91.69M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$46.57M derived: sum of 2 quarters · filed 2026-03-12 | -$72.95M derived: sum of 3 quarters · filed 2026-03-12 | -$97.22M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$25.65M 10-Q · filed 2024-11-07 | -$52.03M derived: sum of 2 quarters · filed 2024-11-07 | -$76.30M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$26.38M 10-Q · filed 2024-08-08 | -$50.65M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$24.27M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$76.25M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |